US$40.89: That's What Analysts Think AtriCure, Inc. (NASDAQ:ATRC) Is Worth After Its Latest Results
US$40.89: That's What Analysts Think AtriCure, Inc. (NASDAQ:ATRC) Is Worth After Its Latest Results
Shareholders might have noticed that AtriCure, Inc. (NASDAQ:ATRC) filed its quarterly result this time last week. The early response was not positive, with shares down 8.3% to US$21.57 in the past week. The results overall were pretty much dead in line with analyst forecasts; revenues were US$116m and statutory losses were US$0.17 per share. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.
股東們可能已經注意到,AtriCure,Inc.(納斯達克代碼:ATRC)在上週發佈了其季度業績報告。早期反應並不積極,股票在過去一週下跌了8.3%,至21.57美元/股。總體結果基本符合分析師預測;收入爲1,1600萬美元,法定虧損爲每股0.17美元。分析師通常在每次盈利報告時更新其預測,我們可以從他們的估計中判斷公司的看法是否改變或是否存在任何新的問題需要注意。因此,我們收集了最新的季度業績預測一致估計,以了解下一年可能會發生什麼。
![big](https://newsfile.futunn.com/public/NN-PersistNewsContentImage/7781/20240801/0-5b9932029024a2ce11a10a7584fd3d46-0-02054dfdf4cfc6f9a79ad709505a3ade.png/big)
Taking into account the latest results, the consensus forecast from AtriCure's nine analysts is for revenues of US$458.1m in 2024. This reflects an okay 6.5% improvement in revenue compared to the last 12 months. The loss per share is expected to ameliorate slightly, reducing to US$0.79. Yet prior to the latest earnings, the analysts had been forecasting revenues of US$461.8m and losses of US$0.78 per share in 2024.
考慮到最新結果,AtriCure的9名分析師的共識預測爲,2024年收入將達到4,5810萬美元。相比過去12個月,收入有6.5%的適度改善。每股虧損預計將略有改善,降至0.79美元。然而,在最新的盈利之前,分析師們一直預測,2024年收入爲4,6180萬美元,每股虧損爲0.78美元。
The analysts trimmed their valuations, with the average price target falling 8.7% to US$40.89, with the ongoing losses seemingly weighing on sentiment, despite no real changes to the earnings forecasts. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. Currently, the most bullish analyst values AtriCure at US$60.00 per share, while the most bearish prices it at US$30.00. This is a fairly broad spread of estimates, suggesting that analysts are forecasting a wide range of possible outcomes for the business.
分析師降低了其估值,平均目標價下降了8.7%,至40.89美元,儘管收益預測沒有實質性變化,持續的虧損似乎仍在壓制情緒。還有一種思考目標價的方法,就是查看分析師提出的目標價範圍,因爲廣泛的估計範圍可能表明對業務可能產生不同看法。目前,最看好的分析師將AtriCure定價爲每股60.00美元,而最看淡的定價爲每股30.00美元。這是一個相當廣泛的估計範圍,表明分析師預測了業務可能出現廣泛的結果。
Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. The period to the end of 2024 brings more of the same, according to the analysts, with revenue forecast to display 14% growth on an annualised basis. That is in line with its 16% annual growth over the past five years. Compare this with the broader industry, which analyst estimates (in aggregate) suggest will see revenues grow 8.2% annually. So it's pretty clear that AtriCure is forecast to grow substantially faster than its industry.
我們可以通過更大的視野來看待這些估計,例如將預測與過去的表現進行比較,以及預測是更樂觀還是更悲觀,相對於行業中的其他公司。分析師預測到2024年完全符合過去五年的每年增長率爲16%的特點。與整個行業進行比較,分析師的估計(總體上)表明,收入年均增長8.2%。因此,AtriCure預計將比其行業增長快得多。
The Bottom Line
最重要的事情是分析師增加了它對下一年每股虧損的估計。令人欣慰的是,營收預測未發生重大變化,業務仍有望比整個行業增長更快。共識價格目標穩定在28.50美元,最新估計不足以對價格目標產生影響。
The most important thing to take away is that the analysts reconfirmed their loss per share estimates for next year. Happily, there were no major changes to revenue forecasts, with the business still expected to grow faster than the wider industry. Furthermore, the analysts also cut their price targets, suggesting that the latest news has led to greater pessimism about the intrinsic value of the business.
最重要的是,分析師爲明年的每股虧損預測再次確認。令人欣慰的是,收入預測沒有發生重大變化,業務仍有望比整個行業快速增長。此外,分析師還降低了其價格目標,表明最新消息導致人們對業務內在價值的看法更爲悲觀。
Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. We have estimates - from multiple AtriCure analysts - going out to 2026, and you can see them free on our platform here.
爲此,我們認爲長期前景比明年的收益更爲相關。我們有估計-來自多個AtriCure分析師-可以延伸至2026年,在此可以免費查看它們。
You still need to take note of risks, for example - AtriCure has 2 warning signs we think you should be aware of.
您仍然需要注意風險,例如-AtriCure有2個警告信號,我們認爲您應該注意。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
譯文內容由第三人軟體翻譯。